<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04273594</url>
  </required_header>
  <id_info>
    <org_study_id>CP-100-008</org_study_id>
    <nct_id>NCT04273594</nct_id>
  </id_info>
  <brief_title>FemBlocÂ® Permanent Contraception Trial</brief_title>
  <acronym>BLOC</acronym>
  <official_title>BLOC: Prospective, Multi-Center, Study of Subjects Undergoing FemBloc Permanent Contraception With Two Confirmation Procedures (FemBloc With FemChec and Fluoro HSG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Femasys Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Femasys Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if changes to the FemBloc Permanent Contraceptive
      System are effective in increasing reliance (the ability of a woman to be able to depend on
      FemBloc for contraception once the treatment and confirmation test have been performed), and
      decreasing pregnancy rate. In addition, the study will compare the FemChec confirmation
      procedure to that of fluoroscopic HSG, a well-established method of confirmation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reliance Rate</measure>
    <time_frame>within 1 year</time_frame>
    <description>Number of subjects told to rely divided by number of qualified subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concordance</measure>
    <time_frame>within 1 year</time_frame>
    <description>Concordance of Fluoroscopic HSG to FemBloc confirmation with FemChec</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>FemBloc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational device and procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FemBloc</intervention_name>
    <description>Treatment with FemBloc for women who desire permanent birth control (female sterilization)</description>
    <arm_group_label>FemBloc</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, 21 - 45 years of age desiring permanent birth control

          -  Sexually active with male partner

          -  Regular menstrual cycle for last 3 months or on hormonal contraceptives

        Exclusion Criteria:

          -  Uncertainty about the desire to end fertility

          -  Known or suspected pregnancy

          -  Prior tubal surgery, including sterilization attempt

          -  Prior endometrial ablation

          -  Presence, suspicion, or previous history of gynecologic malignancy

          -  Abnormal uterine bleeding requiring evaluation or treatment

          -  Scheduled to undergo concomitant intrauterine procedures at the time of procedure(s)

          -  Allergy to shellfish, betadine or iodinated contrast
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>770-500-3910</phone>
    <phone_ext>146</phone_ext>
    <email>studysupport@femasys.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Stamford Hospital</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Women's Health Advantage</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals - Cleveland Medical Center</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>permanent contraception</keyword>
  <keyword>birth control</keyword>
  <keyword>pregnancy prevention</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

